• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Sodium-glucose cotransporter 2 inhibitors may improve left ventricular diastolic function in hypertrophic cardiomyopathy

byAlex XiangandSimon Pan
February 17, 2026
in Cardiology, Chronic Disease, Pharma
Reading Time: 2 mins read
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Share on FacebookShare on Twitter

1. Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) were associated with improved left ventricular diastolic function and New York Heart Association (NYHA) class in patients with hypertrophic cardiomyopathy (HCM).

Evidence Rating Level: 2 (Good)

Current management of HCM includes symptom control with beta-blockers and calcium channel blockers, and risk reduction through invasive procedures such as septal reduction therapy and implantable cardioverter-defibrillators. SGLT-2i have been shown to have strong cardioprotective properties in heart failure; however, these pivotal trials excluded patients with HCM. This single-center retrospective cohort study included patients aged 18 or older with HCM and no prior exposure to SGLT-2i. After propensity score-matching, 188 patients were included. 94 patients (mean [SD] age, 69.0 [14.0] years; 34% female) were started on an SGLT-2i during admission, and 94 patients (mean [SD] age, 65.4 [14.8] years; 30.9% female) were not. The primary endpoints were mitral annular tissue velocity (e′), early diastolic mitral inflow velocity (E)/e′, interventricular septal thickness (IVST), and NYHA class. At 6-months, the SGLT-2i group exhibited significantly greater improvements in septal e′ (0.7 ± 1.3 vs. Δ0.04 ± 1.6, p = 0.002), E/e′ (–5.1 ± 8.7 vs. 0.4 ± 6.4, p < 0.001), IVST (–1.3 (–3.1 to 0) mm vs. −0.2 (–2.0 to 0.9) mm, p = 0.005), NYHA class (−1(−1 to −0.25) vs. −1 (−1 to 0), p = 0.031), and BNP levels (0 (–607.5 to 0) pg/mL vs. 0 (–105.7 to 0) pg/mL, p = 0.023). No hypoglycemia and urinary tract infection events were recorded in either group, and no significant changes in creatinine were observed (2.3 ± 15.7 vs. 0.3 ± 15.4 mg/dL, p = 0.38).

Click here to read this study in Frontiers in Cardiovascular Medicine

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Chronic exposure to particulate matter is associated with increased cardiovascular risk

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

A medical care at home program following hospitalization with acute decompensated heart failure may offer a safe and effective alternative to continued hospitalization

Tags: cardiologydiastolic dysfunctionhypertrophic cardiomyopathysodium-glucose cotransporter 2 (SGLT2) inhibitors
Previous Post

2MM: AI Roundup- Medtronic’s AI-Robotic Spine Platform, 90% Phase I Success for AI-Designed Drugs, and UCSD’s AI Cancer Risk Predictor [Feb 17th, 2026]

Next Post

FDA clears Medtronic stealth AXiS AI-Robotic spine system

RelatedReports

Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

A medical care at home program following hospitalization with acute decompensated heart failure may offer a safe and effective alternative to continued hospitalization

July 24, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Catheter ablation within 1 year of atrial fibrillation diagnosis is associated with reduced risk of recurrence

July 24, 2026
Next Post
2 Minute Medicine AI Roundup editorial illustration

FDA clears Medtronic stealth AXiS AI-Robotic spine system

Brain lesions on MRI linked with subsequent increased stroke risk

Two plasma-based biomarkers may accurately predict positive CT head scans in traumatic brain injury

2 Minute Medicine AI Roundup editorial illustration

Artificial intelligence designed drugs Hit 90% Phase I success rate in trials

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
  • A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.